S
Shin-Shay Tian
Researcher at GlaxoSmithKline
Publications - 7
Citations - 664
Shin-Shay Tian is an academic researcher from GlaxoSmithKline. The author has contributed to research in topics: Receptor & Signal transduction. The author has an hindex of 7, co-authored 7 publications receiving 604 citations.
Papers
More filters
Journal ArticleDOI
Preclinical activity of eltrombopag (SB-497115), an oral, nonpeptide thrombopoietin receptor agonist.
Connie L. Erickson-Miller,Evelyne Delorme,Shin-Shay Tian,Christopher B. Hopson,Amy J. Landis,Elizabeth I. Valoret,Teresa S. Sellers,Jon Rosen,Stephen G. Miller,Juan I. Luengo,Kevin J. Duffy,Julian Jenkins +11 more
TL;DR: In conclusion, eltrombopag interacts selectively with the TpoR without competing with Tpo, leading to the increased proliferation and differentiation of human bone marrow progenitor cells into megakaryocytes and increased platelet production.
Journal ArticleDOI
Discovery and characterization of a selective, nonpeptidyl thrombopoietin receptor agonist.
Connie L. Erickson-Miller,Evelyne Delorme,Shin-Shay Tian,Christopher B. Hopson,Kenneth C. Stark,Leslie Giampa,Elizabeth I. Valoret,Kevin J. Duffy,Juan L. Luengo,Jon Rosen,Stephen G. Miller,Susan B. Dillon,Peter Lamb +12 more
TL;DR: SB 394725, a small molecule with a molecular weight of 452 Da, is capable of activating Tpo-specific signal transduction, proliferation, and differentiation responses similar to the responses and functions of the protein growth factor, Tpo.
Journal ArticleDOI
Hydrazinonaphthalene and azonaphthalene thrombopoietin mimics are nonpeptidyl promoters of megakaryocytopoiesis.
Kevin J. Duffy,Michael G. Darcy,Evelyne Delorme,Susan B. Dillon,Daniel F. Eppley,Connie L. Erickson-Miller,Leslie Giampa,Christopher B. Hopson,Yifang Huang,Richard M. Keenan,Peter Lamb,Lynnette Leong,Nannan Liu,Stephen G. Miller,Price Alan T,Jon Rosen,Rakhi Shah,Tony Shaw,Heather Smith,Kenneth C. Stark,Shin-Shay Tian,Curtis M. Tyree,Kenneth Wiggall,Lily Zhang,Juan I. Luengo +24 more
TL;DR: Modification of the core structure and adjustment of unwanted functionality resulted in the development of (5-oxo-1,5-dihydropyrazol-4-ylidene)hydrazines which exhibited efficacies equivalent to those of TPO in several cell-based assays designed to measure thrombopoietic activity.
Journal ArticleDOI
Species Specificity and Receptor Domain Interaction of a Small Molecule TPO Receptor Agonist.
Connie L. Erickson-Miller,Evelyn Delorme,Maya Iskander,Leslie Giampa,Christpher B. Hopson,Juan I. Luengo,Kevin J. Duffy,Susan B. Dillon,Jon Rosen,Stephen D. Miller,Peter J. Lamb,Shin-Shay Tian +11 more
TL;DR: In this article, a series of chimeric TpoR chimeric receptors were constructed in which the complement receptor homology region 1 (CRH1), CRH2 and the transmembrane (TM) and cytoplasmic domains were interchanged.
Journal ArticleDOI
Biological Activity and Selectivity for Tpo Receptor of the Orally Bioavailable, Small Molecule Tpo Receptor Agonist, SB-497115.
Connie L. Erickson-Miller,Evelyn Delorme,Leslie Giampa,Christopher B. Hopson,Elizabeth I. Valoret,Shin-Shay Tian,Stephen G. Miller,Richard M. Keenan,Jon Rosen,Susan B. Dillon,Kevin J. Duffy,Peter J. Lamb,Juan I. Luengo +12 more
TL;DR: SB-497115 is the first non-peptide small molecule TpoR agonist to demonstrate activity in human in vitro bone marrow assays and demonstrate pharmacological activity in humans.